Loading…
BioCryst Pharmaceuticals, Inc. is projected to rise to $13.34 by 2027, a +28% move from its current price of $10.45. BCRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $10.16 | $10.46 | $10.76 | +0.05% |
| Jul 13 | $10.05 | $10.46 | $10.89 | +0.10% |
| Jul 14 | $9.96 | $10.47 | $10.99 | +0.15% |
| Jul 15 | $9.89 | $10.47 | $11.08 | +0.21% |
| Jul 16 | $9.83 | $10.48 | $11.16 | +0.26% |
| Jul 17 | $9.78 | $10.48 | $11.24 | +0.31% |
| Jul 18 | $9.73 | $10.49 | $11.30 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.73 | $10.49 | $11.30 | +0.36% |
| Week 2 | $9.47 | $10.53 | $11.70 | +0.72% |
| Week 3 | $9.28 | $10.56 | $12.03 | +1.09% |
| Week 4 | $9.13 | $10.60 | $12.32 | +1.45% |
| Week 5 | $9.00 | $10.64 | $12.58 | +1.82% |
| Week 6 | $8.89 | $10.68 | $12.83 | +2.18% |
| Week 7 | $8.79 | $10.72 | $13.07 | +2.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for hereditary angioedema (HAE) and other rare diseases. It markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names.
BioCryst also markets ORLADEYO, an oral serine protease inhibitor to treat HAE. BioCryst is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; and STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc.
was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on rare disease medicines. It trades at $10.99 and has a market capitalization of $2.79B, ranking 1815. The current price and the near-term forecast point to a path of upside that is reflected in the long-range forecast, with average prices rising from $10.99 in 2026 to $21.86 in 2030 and to $153.51 in 2050, and with maximums reaching as high as $32.30 in 2030, $143.74 in 2040, and $291.93 in 2050.
A major floor 33.0% below — a decisive break under it would weaken the trend.
The nearest floor, 21.6% below — buyers have tended to step in here.
The nearest ceiling, 6.3% above — a clean break opens room to run.
A major ceiling 22.8% above — clearing it would confirm fresh momentum.
Key BCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.69 | Sell | $10.55 | Sell |
| MA 10 | $10.24 | Buy | $10.29 | Buy |
| MA 20 | $9.69 | Buy | $9.86 | Buy |
| MA 50 | $9.14 | Buy | $9.34 | Buy |
| MA 100 | $9.01 | Buy | $8.94 | Buy |
| MA 200 | $8.08 | Buy | $8.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.79 | Neutral |
| Stoch RSI (14) | 19.80 | Buy |
| CCI (20) | 81.57 | Neutral |
| Williams %R (14) | -33.50 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | 12.24 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 66.50 | Neutral |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 1.48 | Buy |
| Ultimate (7,14,28) | 61.51 | Neutral |
| Momentum (10) | 0.55 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 11.08 | Sell |
| ADX (14) | 23.11 | Buy |
| ATR (14) | 0.28 | Info |
The 30-day technical picture for BioCryst shows bullish sentiment with RSI(14) at 70. The stock trades around key moving averages, with a SMA50 of $9.03 and a SMA200 of $8.04. Immediate support sits at $8.19 and resistance at $10.99. Over the last 30 days, the price has fluctuated between $9.05 and $13.34.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.24 | $10.45 | $13.82 | 0% | Neutral | |
| $10.58 | $13.34 | $17.82 | +28% | Bullish | |
| $10.90 | $14.14 | $19.62 | +35% | Bullish | |
| $12.12 | $16.12 | $23.04 | +54% | Bullish | |
| $13.48 | $18.30 | $26.82 | +75% | Bullish | |
| $13.99 | $19.38 | $29.03 | +85% | Bullish | |
| $18.17 | $25.62 | $39.14 | +145% | Bullish | |
| $21.49 | $30.82 | $47.92 | +195% | Bullish | |
| $21.90 | $31.92 | $50.46 | +206% | Bullish | |
| $23.25 | $34.42 | $55.23 | +229% | Bullish | |
| $37.34 | $59.32 | $101.41 | +468% | Bullish | |
| $58.37 | $104.73 | $196.33 | +902% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.24 | $10.45 | $12.51 | +0.00% |
| August 2026 | $8.91 | $10.53 | $12.79 | +0.75% |
| September 2026 | $9.20 | $10.95 | $13.45 | +4.02% |
| October 2026 | $9.35 | $11.20 | $13.89 | +2.27% |
| November 2026 | $9.12 | $10.98 | $13.73 | -1.93% |
| December 2026 | $9.07 | $10.97 | $13.82 | -0.12% |
Click any year to see its month-by-month BCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BCRX could reach as high as $13.82, with a base case around $10.45 and support toward $6.24 — roughly 0% from $10.45. Price action looks broadly range-bound.
Expect BCRX to range from $10.58 to $17.82 through 2027. The $13.34 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BCRX price prediction for 2028 points to an average of $14.14 (low $10.90, high $19.62) — a potential gain of +35% on today's $10.45. Momentum favours further upside here.
In 2029, BCRX is projected to trade between $12.12 and $23.04, averaging $16.12 — a potential gain of +54% from today's $10.45. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
BioCryst Pharmaceuticals, Inc.'s 2030 outlook centres on $18.30, within a $13.48 to $26.82 range. That is up +14% on the projected 2029 average. That marks a +75% change versus current levels. Momentum favours further upside here.
By 2031, BCRX could reach as high as $29.03, with a base case around $19.38 and support toward $13.99 — roughly +85% from $10.45. Buyers look set to stay in control over this stretch.
Expect BCRX to range from $18.17 to $39.14 through 2032. The $25.62 average target implies a +145% move from current prices. That is up +32% on the projected 2031 average. Momentum favours further upside here.
The BCRX price prediction for 2033 points to an average of $30.82 (low $21.49, high $47.92) — a potential gain of +195% on today's $10.45. Buyers look set to stay in control over this stretch.
In 2034, BCRX is projected to trade between $21.90 and $50.46, averaging $31.92 — a potential gain of +206% from today's $10.45. That is up +4% on the projected 2033 average. Momentum favours further upside here.
BioCryst Pharmaceuticals, Inc.'s 2035 outlook centres on $34.42, within a $23.25 to $55.23 range. That is up +8% on the projected 2034 average. That marks a +229% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BCRX could reach as high as $101.41, with a base case around $59.32 and support toward $37.34 — roughly +468% from $10.45. Momentum favours further upside here.
Expect BCRX to range from $58.37 to $196.33 through 2050. The $104.73 average target implies a +902% move from current prices. That is up +77% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCRX today (≈ 95.69378 BCRX) could be worth
$10,022.26
+$9,022.26 (+902%) by 2050 · US Dollar
Based on the average projected BCRX price of $104.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCRXwould be worth at today's price.
$1,000 invested in BCRX on Jul 10, 2025 (≈ 112.612611 BCRX) would be worth
$1,176.8
+$176.8 (+17.7%) today · 1.18× · US Dollar
Based on a BCRX entry price of $8.88 vs. today's $10.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.84 | $1,061.99 | +6.2% |
| 1 month ago | $8.19 | $1,275.95 | +27.6% |
| 3 months ago | $9.56 | $1,093.1 | +9.3% |
| 6 months ago | $7.09 | $1,473.91 | +47.4% |
| 1 year ago | $8.88 | $1,176.8 | +17.7% |
| All time (5.0y) ago | $15.8 | $661.39 | -33.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCRX forecast.
Our base-case forecast reaches $21.00 around 2032.
Implied market cap at $21.00: $5.34B
The multi-year forecast presents a bullish trajectory through 2030, 2040 and 2050. In 2030 the average price is projected at $21.86 with a min of $15.98 and a max of $32.30, delivering an ROI of 98.9%. By 2040 the average price is $83.06 (min $51.54, max $143.74) with a 655.8% ROI.
By 2050 the average price is $153.51 (min $83.75, max $291.93) and the ROI rises to 1296.8%. Sentiment is BULLISH in 2027 through 2050 and NEUTRAL in 2026; these are estimates and not guarantees.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $21.86, with a min of $15.98 and a max of $32.30; the implied ROI is 98.9%.
The forecast shows bullish sentiment in 2027 through 2050, with the average price rising to $153.51 by 2050 and an ROI of 1296.8%. In 2026 the year starts neutral at $10.99 average. These figures are estimates, not guarantees.
Yes. The forecast max price reaches $143.74 in 2040 and $291.93 in 2050, indicating the potential to exceed $100 by 2040.
For 2035 the average price is projected at $45.30 with a range from $30.26 to $73.46, and a 312.2% ROI.
Current price is $10.99 and market capitalization is $2.79B.
BioCryst Pharmaceuticals, Inc. Community Discussion
0Share your BioCryst Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.